High Impact Practices Student Showcase Spring 2025

Cytarabine in children with Acute Promyelocytic Leukemia

Cytarabine in children with Acute Promyelocytic Leukemia

Streaming Media

Link to Full Text

Download Full Text

Course Code

HSC

Course Number

4930

Faculty/Instructor

Professor Steven Burroughs

Faculty/Instructor Email

Steven.Burroughs@ucf.edu

About the Author

We are students at UCF College of Health Professions and Sciences, in the class of Professor Steven Burroughs HSC 4930, who helped us on our research projects and encouraged us to participate in this showcase. We are also extending our gratitude to HIP department who assisted us in this process.

Authors: Erika Brandt, Bojana Kovacevic, Kaylee Albrecht

Abstract, Summary, or Creative Statement

Leukemia is a form of blood cancer, originating in the bone marrow, and

accounts for over 30% of all cancer diagnoses in children. While there are

many forms of treatment which may be used to treat Leukemia,

chemotherapy is the most common and most effective form. The “gold

standard” treatment for pediatric Leukemia, specifically Acute Promyelocytic

Leukemia, is Daunorubicin (DNR). Another chemotherapy drug, which is

used only in combination with DNR, is Cytarabine (Ara-C). Due to the

aggressive nature of treatment, there are a number of side effects.

This clinical trial seeks to determine the non-inferiority of

DNR alone, as the addition of Ara-C significantly increases the risk for

severe side effects.As a result of the intensive research we have learned to

differentiate between different types of research, understand how to

read and gather information from clinical trials, and perform

comparative analyses of clinical trials in addition to gaining a

comprehensive knowledge on Leukemia itself.

Additionally, we have developed a

heightened awareness of identifying potential biases in research which

may alter the delivery of certain results. We have gained a thorough

understanding of the ethical principles behind different treatment protocols

which has absolutely prepared us to be better clinicians.

Together, we have identified significant room for improvement on the

current status of global standards of care, and we seek to be more critical

consumers of research in the future. We certainly see the impact potential of

what we have learned far beyond the scope of the classroom.

Keywords

Leukemia;pediatric;Cytarabine;chemo;Ara-C;health;side effects;study

Cytarabine in children with Acute Promyelocytic Leukemia


Share

COinS